Company: VRCA
Filing Date: 2025-12-23
Form Type: 424B3
Source: 0001193125-25-330986
Chunk: 11

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-23
Form: 424B3
Chunk 11
---
 shares of our common stock                                                                                                                                        
 issued to Mr. Zawitz in the Private Placement, (b) 2,500 shares of our common stock issuable upon exercise of Common Warrants issued to Mr. Zawitz in the Private Placement, (c) 11,000 shares of our common stock held by Mr. Zawitz  
 prior to the Private Placement (d) 25,728 shares of common stock issuable upon the exercise of options within 60 days of December 1, 2025 and (e) 2,500 shares of our common stock issuable upon exercise of Series B warrants held by 
 Mr. Zawitz prior to the Private Placement.                                                                                                                                                                                             |

| (7) | “Beneficial Ownership Prior to this Offering” consists of (a) 3,536 shares of our common stock                                                                                                                                           
 issued to Mr. Kirby in the Private Placement, (b) 884 shares of our common stock issuable upon exercise of Common Warrants issued to Mr. Kirby in the Private Placement and (c) 5,426 shares of our common stock held by Mr. Kirby prior 
 to the Private Placement.                                                                                                                                                                                                                |

8

| (8) | “Beneficial Ownership Prior to this Offering” consists of (a) 2,357 shares of our common stock                                                                                                                                                  
 issued to Dr. Rosenberg in the Private Placement, (b) 589 shares of our common stock issuable upon exercise of Common Warrants issued to Dr. Rosenberg in the Private Placement and (c) 6,770 shares of common stock issuable upon the exercise 
 of options within 60 days of December 1, 2025.                                                                                                                                                                                                  |

| (9) | “Beneficial Ownership Prior to this Offering” consists of (a) 923,910 shares of our common stock                                                                                                                                                          
 held by Caligan Partners Master Fund LP (the “Caligan Fund”) and certain accounts (the “Caligan Accounts”) managed by Caligan Partners LP (“Caligan”) prior to the Private Placement, (b) 421,346 shares of our                                           
 common stock issuable upon exercise of Series B warrants held by the Caligan Fund and the Caligan Accounts prior to the Private Placement, (c) 4,126,239 shares of our common stock issuable upon exercise of                                             
 Pre-Funded Warrants issued to the Caligan Fund and the Caligan Accounts in the Private Placement and (d) 1,031,559 shares of our common stock iss